Refractory Chronic Graft Versus Host Disease Therapeutics
1. Rezurock patent expiration
Treatment: Treatment of chronic graft-versus-host disease (chronic gvhd) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 12 years and older with a grade 3 infection ...
REZUROCK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8357693 | KADMON PHARMS LLC | Pharmacokinetically improved compounds |
Jun, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12097202 | KADMON PHARMS LLC | Methods of administering Belumosudil for treatment of chronic graft versus host disease |
Jul, 2042
(16 years from now) | |
| US11311541 | KADMON PHARMS LLC | Treatment of GVHD |
Apr, 2035
(9 years from now) | |
| US10696660 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(7 years from now) | |
| US10183931 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(7 years from now) | |
| US9815820 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity(ODE-362) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: 16 July, 2025
Market Authorisation Date: 16 July, 2021
Dosage: TABLET
More Information on Dosage
REZUROCK family patents
